ENLV
Enlivex Therapeutics Ltd
NASDAQ: ENLV · HEALTHCARE · BIOTECHNOLOGY
$0.82
-0.46% today
Updated 2026-05-01
Market cap
$197.61M
P/E ratio
0.03
P/S ratio
—
EPS (TTM)
$25.48
Dividend yield
—
52W range
$1 – $2
Volume
0.6M
Enlivex Therapeutics Ltd (ENLV) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
126.20%
ROA
-0.80%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2002 | $18.14M | — | 78.28% | — | — |
| 2003 | $13.53M | — | 56.59% | — | — |
| 2004 | $14.53M | — | 77.59% | — | — |
| 2005 | $25.30M | — | 71.73% | — | — |
| 2006 | $17.18M | — | 62.57% | — | — |
| 2007 | $18.73M | — | 52.95% | — | — |
| 2012 | — | $-229000.00 | — | — | — |
| 2013 | — | $-1.15M | — | — | — |
| 2014 | — | $-7.02M | — | — | — |
| 2015 | — | $-15.37M | — | — | — |
| 2016 | $0.00 | $-16.02M | — | — | — |
| 2017 | $0.00 | $-5.95M | — | — | — |
| 2018 | $0.00 | $-4.90M | — | — | — |
| 2019 | $0.00 | $-9.38M | — | — | — |
| 2020 | $2.28M | $-11.82M | -12.56% | -429.73% | -519.28% |
| 2021 | $0.00 | $-14.47M | — | — | — |
| 2022 | $0.00 | $-31.06M | — | — | — |
| 2023 | $0.00 | $-29.07M | — | — | — |
| 2024 | $0.00 | $-15.01M | — | — | — |
| 2025 | $0.00 | $1.24B | — | — | — |